DLA Piper advises Genomma Lab in authorization for registered public note offering

DLA Piper advised Genomma Lab Internacional S.A.B. de C.V., a Mexican pharmaceutical and personal care company with an international presence, in obtaining authorization from the Mexican National Banking and Securities Commission (CNBV) to register a revolving issued program, which will enable the company to make a public offering of short- and long-term senior notes valued at US$523 million (MX$10 billion).

The CNBV recognized Genomma as a recurrent issuer, which will enable the company to better take advantage of windows of opportunity for financing within the Mexican Stock Exchange.

The DLA Piper team representing Genomma Lab was led by partner Xavier Mangino (Mexico City) and included consultant Cristian Gastelum (Mexico City).